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T-cells are central players in the immune response against both pathogens and cancer.Their
speciﬁcity is solely dictated by theT-cell receptor (TCR) they clonally express. As such, the
genetic modiﬁcation ofT lymphocytes using pathogen- or cancer-speciﬁcTCRs represents
an appealing strategy to generate a desired immune response from peripheral blood lym-
phocytes. Moreover, notable objective clinical responses were observed in terminally ill
cancer patients treated with TCR-gene modiﬁed cells in several clinical trials conducted
recently. Nevertheless, several key aspects of this approach are the object of intensive
research aimed at improving the reliability and efﬁcacy of this strategy. Herein, we will sur-
vey recent studies in the ﬁeld of TCR-gene transfer dealing with the improvement of this
approach and its application for the treatment of malignant, autoimmune, and infectious
diseases.
Keywords:T-cell receptor,TCR-gene transfer,T-cells, immunotherapy, cancer, infectious diseases, autoimmunity
INTRODUCTION – TCR-GENE TRANSFER FROM
BENCH TO BEDSIDE
As an integral part of the adaptive immune system, T-cells have
been attributed several protective functions directed against both
microbial pathogens and tumor cells. Although derived from the
self, neoplastic cells often express tumor antigens that can dis-
criminate them from normal tissues and can be recognized by
the adaptive immune system (Novellino et al., 2005). Indeed, T
lymphocytes demonstrate the capacity to eradicate cancer cells
and a growing body of studies has shown that the adoptive cell
transfer (ACT) of tumor-speciﬁc T lymphocytes (Hawkins et al.,
2010; Restifo et al., 2012) isolated from the tumor itself has been
demonstrated tomediate impressive tumor regression in advanced
melanoma patient, with almost a quarter of the treated individu-
als durable complete responders (Rosenberg et al., 2011). Clinical
trials based on adoptive T-cell transfer have been conducted in the
last two decades for the treatment of viral conditions (Fujita et al.,
2008; Berger et al., 2009), especially in the context of bone mar-
row transplantation. Initially targeting cytomegalovirus (CMV;
Walter et al., 1995), this strategy has been extended to other viruses
such as Epstein–Barr virus (EBV;Heslop et al., 1996), adenoviruses
(Feuchtinger et al., 2006), and multiple viruses simultaneously
(Leen et al., 2006).
Still, the isolation of such antigen-speciﬁc T-cells is not always
possible and as such, alternative approaches have been designed
to enable the generation of antigen-speciﬁc lymphocytes from
peripheral T-cells. T lymphocytes can recognize their cognate
Abbreviations: CTL, cytotoxic T-cells; HLA, human leukocyte antigen; MHC,major
histocompatibility complex; OR, objective response; TCR, T-cell receptor.
antigen through the binding of their T-cell receptor (TCR) to an
epitope presented by major histocompatibility complex (MHC)
molecules on the target cells (Vyas et al., 2008). This implies that
the TCR dictates the speciﬁcity of a given T-cell and that it should
prove feasible to provide T-cells with new speciﬁcities by trans-
ferring the genes of a given TCR. The successful reprogramming
of T-cell speciﬁcity by TCR-gene transfer was ﬁrst demonstrated
by Steinmetz and colleagues in a murine system (Dembic et al.,
1986). Originally, the purpose of this reportwas to study the recep-
tor dynamics, but it opened a novel ﬁeld of therapeutic research
dealing with gene-mediated redirection of T-cell speciﬁcity. This
approach was then applied to endow T-cells with tumor speci-
ﬁcity using a melanoma-speciﬁc TCR in vitro (Clay et al., 1999),
and subsequently in vivo, using an inﬂuenza virus-speciﬁc receptor
(Kessels et al., 2001).
Basically, this strategy relies on the isolation of the genes encod-
ing the α and β chains of a TCR speciﬁc for an antigen from
a T-cell clone (e.g., from tumor-inﬁltrating lymphocytes (TILs),
peptide-stimulated PBLs from healthy individuals or from immu-
nized human leukocyte antigen (HLA)-transgenic mouse). While
the rapid isolationof suitableTCRs for therapy remains a challenge
due in part to their high variability (around 40–50 different frame-
work genes for either the α or the β), multiple strategies (mainly
using sets of primers for TCR-5′ regions or the rapid-ampliﬁcation
of cDNA ends – RACE) have been published (Aarnoudse et al.,
2002; Boria et al., 2008; Birkholz et al., 2009; Walchli et al., 2011).
Then, these α and β chains are cloned into an expression vec-
tor and transduced to previously stimulated normal peripheral
T lymphocytes. This enables the reprogramming of the adap-
tive immune response against antigens of choice based on the
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speciﬁcity of the introduced TCR (reviewed elsewhere; Schmitt
et al., 2009; Udyavar and Geiger, 2010; Thomas et al., 2010). Sev-
eral clinical studies were elaborated based on this conceptual
approach for the treatment of advanced cancer patients: Morgan
et al. (2006) demonstrated for the ﬁrst time that it was possible
to transduce normal autologous PBLs from stage IV-metastatic
melanoma patients with an MART1-speciﬁc TCR and generate
large numbers of MART1-speciﬁc cells (109–1010) to be infused
back to the patients. In this Phase I clinical trial, 17 metastatic
melanoma patients were treated and 2 of them (12%) demon-
strated dramatic tumor regression leading to an objective clinical
response. This was followed by a second study in which the same
group made use of two high-afﬁnity TCRs against the melanoma
antigens MART-1 and gp100 (Johnson et al., 2006) (including an
HLA-A2/gp100154-speciﬁc murine TCR) in a clinical trial (John-
son et al., 2009) in which the objective response (OR) rate raised
to 30% of the patients treated. Recently, more clinical studies
were aimed at exploring the therapeutic potential of TCR-gene
transfer to target other cancers than melanoma, using carcinoem-
bryonic (CEA)- (Parkhurst et al., 2011a), p53- (Davis et al., 2010),
and NY-ESO- (Robbins et al., 2011) speciﬁc TCRs. The CEA-TCR
and p53-TCR were based on murine TCRs isolated in HLA-A2
transgenic hosts and in each study, one patient responded to the
treatment. Still, the CEA-TCR clinical trial was limited to only
three patients, due to severe inﬂammatory colitis. Such toxicity
emphasizes the possible on-target effects of such therapy. How-
ever, Robbins et al. (2011) reported encouraging results using
an afﬁnity-enhanced NY-ESO-1-speciﬁc TCR. Half (5/11) of the
melanomapatients treated aswell as 67%of the synovial cell cancer
patients underwent an objective clinical response, with two com-
plete responders. Notably, no toxicities were observed in all the
patients treated.
Thus far, it has been reported thatmore than a hundred patients
have been treated by the Rosenberg group in the Surgery Branch
at NCI using TCR-gene transfer (Park et al., 2011). Nevertheless,
several hurdles that may hinder the efﬁcacy of these treatments
have been identiﬁed along the years and several studies have
attempted to solve these issues that include the type of the vec-
tor to be used, its conﬁguration, the safety of the procedure, TCR
chains mispairing, and the desired functional avidity of the repro-
grammed cells. In the present review, we will aim at giving an
overview of the recent development in this ﬁeld and will also elab-
orate on the development of TCR-gene engineering for conditions
other than neoplastic diseases.
MANIPULATING THE FUNCTIONAL AVIDITY OF THE
TCR-ENGINEERED CELLS
One of the central questions that pertain to TCR-based gene
modiﬁcations of lymphocytes is to what extent it is possible for
the introduced TCR to reach similar levels of surface expression
and functionality as the endogenous one. As T-cell functional
avidity is dictated mainly by both TCR afﬁnity and the num-
ber of TCR molecules expressed (Schodin et al., 1996), much
efforts has been devoted to improving these biophysical proper-
ties in TCR-engineered cells using two important approaches: the
improvement of TCR afﬁnity and expression and the enhance-
ment of TCR chain pairing and expression. Based on in vitro
comparative assays (Johnson et al., 2006) and the recent solu-
tion of the crystal structure (Borbulevych et al., 2011) of a highly
avid (DMF5) and a medium-avid (DMF4) MART1-speciﬁc TCRs,
and on the other hand the results obtained in two clinical trials
published using these TCRs (Morgan et al., 2006; Johnson et al.,
2009), it is reasonable to surmise that the use of TCRs that endow
T-cells with superior functional avidity might help to improve
OR rates [i.e., 30% OR for the DMF5 (Johnson et al., 2009) com-
pared to 12% for the DMF4 (Morgan et al., 2006)]. In addition,
TCR afﬁnity increase can assist in augmenting T-cell sensitivity
to tumors and in compensating for sub-optimal TCR expression.
Such high-afﬁnity TCR should also function in CD8-negative cells
such as Th1 or Th17, providing additional support for the anti-
tumor response (Cohen et al., 2005; Kuball et al., 2005; Udyavar
et al., 2009). Several approaches to increase the functional avidity
of TCR-engineered cells have been described lately (summarized
in Figure 1).
TCR AFFINITY MATURATION
Because most of the tumor antigens are self antigens, the iso-
lation of high-afﬁnity TCR reactive against tumor antigen from
human donors can represent a major challenge, since high-avidity
CTLs speciﬁc for tumor cells may be deleted by negative selec-
tion. However, it is possible to increase TCR afﬁnity by mutating
selectively amino acids in polymorphic TCR complementarily
determining regions – CDRs (Chlewicki et al., 2005). The screen-
ing of mutated TCRs using yeast or phage-display libraries can
yield afﬁnity improvement up to supra-physiological levels (Holler
et al., 2000; Li et al., 2005). For example, Li et al. (2005) isolated
NY-ESO-speciﬁc TCR with afﬁnities in the picomolar range. Sim-
ilarly, a Gag-speciﬁc TCR that underwent a 360-fold increase
in afﬁnity demonstrated a more efﬁcient control of the spread
of HIV virus in vitro (Varela-Rohena et al., 2008). Nevertheless,
such afﬁnity increase can prove detrimental to T-cell function by
endowing T-cells with non-speciﬁc/self-reactivities (Zhao et al.,
2007a) or, paradoxically, by causing defective recognition of low
concentrations of antigen (Thomas et al., 2011). In parallel, some
studies demonstrated the beneﬁt of introducing a reduced num-
ber of CDR-targeted mutations; Robbins et al. (2008) increased
the afﬁnity of several TCR by several fold using an alanine-scan
of CDR regions and site-directed mutagenesis of only one to two
residues. This approach was used to increase the afﬁnity of two
TCRs, a CEA- and an NY-ESO1-speciﬁc TCRs, which were sub-
sequently used in recent clinical trials (Parkhurst et al., 2011b;
Robbins et al., 2011) in which several patients underwent clin-
ical objective tumor regression. Another work recently showed
that TCRs seldom express a glycine residue at position 107 in
the CDR3β instead of serine. Based on modeling and molecular
dynamics simulation, a G107S replacement led to 10–1,000-
fold increase in antigen sensitivity in three of four TCRs tested
(Alli et al., 2011).
ISOLATION OF TCRs FROM HLA-MISMATCHED- OR
TRANSGENIC DONORS
High-afﬁnity TCRs could be isolated from HLA-mismatched
donors (Sadovnikova and Stauss, 1996; Savage et al., 2004; Amir
et al., 2011), HLA-transgenic mice (Theobald et al., 1995) or
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FIGURE 1 | A summary of optimization strategies forTCR expression and
pairing.The naturally expressed/endogenousTCR is depicted in gray and the
introduced/exogenousTCR in blue/purple. TM, transmembrane; sc,
single chain.
transgenic mice expressing the human TCR repertoire (Li et al.,
2010), as logically, tolerance mechanisms should not inﬂuence
non-self reactivity, provided the targeted MHC/peptide complex
is recognized as foreign. Additionally, several models utilized
HLA-A2 transgenic mice to isolate TCRs, which were revealed to
display CD8-independent characteristics (Sherman et al., 1992).
We and others showed that such murine TCRs can efﬁciently
function in CD4+ cells (Cohen et al., 2005; Kuball et al., 2005;
Johnson et al., 2009).
TCR CODON OPTIMIZATION
The genetic code bears some degrees of degeneration as a deﬁned
amino acid can be encoded by several (synonymous) codons,
which are differentially represented in the cell. Moreover, cryptic
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splicing sites, mRNA secondary structure, and instability motifs
can reduce the expression of proteins. Using algorithms to mod-
ify the DNA sequence of TCRs “silently,” several TCRs have
been “codon-optimized” leading to higher expression levels and
enhanced reactivity both in vitro and in vivo (Scholten et al., 2006;
Jorritsma et al., 2007).
TCR DEGLYCOSYLATION
Based on the fact that TCR glycosylation can reduce TCR expres-
sion and favor its internalization (Daniels et al., 2002), Kuball
et al. (2009) demonstrated that the deletion of some of these
N-glycosylation sites (4–5 total in the constant domain) from
either human or murine TCRs increased the functional avidity
of T-cells transduced with these mutated TCRs.
USE OF “STRONG” TCRs
It appears that certain TCRs (termed “strong TCRs”) can compete
better for surface expression when expressed in the presence of
various other TCRs (Sommermeyer et al., 2006; Heemskerk et al.,
2007). TCR stability is likely to be inﬂuenced by protein dynam-
ics and folding as well as interactions between the TCR-variable
regions. However, it is unclear what determines the “strength” of
a deﬁned TCR a priori.
INCORPORATION OF HYDROPHOBIC MUTATIONS IN THE
TRANSMEMBRANE REGION
The TCR transmembrane regions contain three positively charged
residues that may be associated with the lack of stability of the
entire chains (Soetandyo et al., 2010). We designed an origi-
nal approach to selectively improve exogenous TCR stability by
increasing the hydrophobic nature of the TCRα transmembrane
region. Incorporation of hydrophobic residues at evolutionary-
permissive positions resulted in an enhanced surface expression
of the TCR chains, leading to an improved cellular avidity and
anti-tumor TCR activity (Haga-Friedman et al., 2012).
OPTIMIZATION OF TCR CHAINS PAIRING
One of the central impediments in the TCR-gene transfer strategy
lies with the mispairing of the exogenous α and β TCR chains
(αEX and βEX) with the naturally expressed endogenous TCR
chains (αNAT and βNAT; reviewed in detail in Govers et al., 2010).
Thus, four different αβ dimers can form in the transduced cells:
the endogenous TCR (αNAT/βNAT), the transduced (desired) TCR
(αEX/βEX) as well as two mixed dimers (αEX/βNAT and αNAT/βEX).
Since the surface expression of these TCR necessitates for these
chains to assembly with a limited number of CD3 molecules, the
existence of unproductive forms of TCR leads to reduced levels
of the exogenous TCR. Additionally, two reports recently showed
that these TCRs mixed heterodimers may engender autoimmunity
manifestations and self-reactivity both in a mouse model (Bendle
et al., 2010) and in vitro (van Loenen et al., 2010).
Consequently, many groups, including ours, are involved in
developing approaches to reduce the mispairing effect as well as to
promote the pairing of the exogenous TCR chains. These strate-
gies include the addition of a second disulﬁde bond (Cohen et al.,
2007; Kuball et al., 2007), the “murinization” of all or part of the
TCR constant regions (Stanislawski et al., 2001; Cohen et al., 2006;
Voss et al., 2006; Thomas et al., 2007; Bialer et al., 2010; Sommer-
meyer and Uckert, 2010), the use of a “knob into holes” approach
(Voss et al., 2008), of chimeric TCR-CD3ζ chain (Sebestyen
et al., 2008; Govers et al., 2011) or of single-chain TCRs (Chung
et al., 1994; Voss et al., 2010; Aggen et al., 2012) and have been
described in details in several reviews (Govers et al., 2010; Thomas
et al., 2010; Merhavi-Shoham et al., 2012). In addition, shRNA
sequences can be incorporated into the TCR encoding vector to
knock down the expression of the endogenous TCR (Okamoto
et al., 2009). Lately, another elegant approach to knock down the
endogenous TCR was reported and is based on the use of zinc-
ﬁnger nucleases (ZFNs) that target the endogenous TCRα and β
chains (Provasi et al., 2012).
CO-EXPRESSION OF CD3 CHAINS
The restricted level of CD3 molecules can represent a bottle-
neck for TCR expression. Ahmadi et al. (2011) demonstrated that
increasing the expression of CD3 chains (using polycistronic vec-
tors) can boost the functional avidity of TCR-transduced T-cells
and their in vivo performance.
GENETIC APPROACHES AND TOOLS FOR THE
ENGINEERING OF T-CELLS
The geneticmodiﬁcation of T-cells with a TCRnecessitates reliable
platforms for the transfer of the genetic information. To date,most
of the platforms used for TCR-gene transfer, both for research and
in clinical settings, were based on γ-retroviral vectors such as the
mouse stemcell virus (MSCV)ormyeloproliferative sarcoma virus
(MPSV; Morgan et al., 2006; Uckert and Schumacher, 2009). γ-
retroviral vectors mediate genome integration of the transgene(s),
which enables its long-term expression in the transduced cells. In
this type of vectors, the exact cloning position of the transgene rel-
ative to cis-elements in the retroviral construct appears critical for
proper expression of the TCR (Frankel et al., 2011). Also, retroviral
vectors may demonstrate a risk of insertional mutagenesis, which
can cause dysregulated gene expression and subsequent malig-
nant transformation (Hacein-Bey-Abina et al., 2003). However, it
is important to note that all the recent TCR-gene transfer clini-
cal trials were based on the use of MSCV-based retroviral vectors
(Park et al., 2011) and that no signs of lymphoproliferative disease
were noted in the patients treated. Additionally, a comprehensive
body of evidence support the notion that no replicative compe-
tent retroviruses (RCR) or adverse events have been observed in
a considerable number of clinical trials (Bear et al., 2012). Still,
primary lymphocyte stimulation is essential when using γ-
retroviral vectors and the latter may shift the T-cell phenotype
causing some levels of T-cells exhaustion (Gattinoni et al., 2005;
Hinrichs et al., 2011). Interestingly, the TCR transgene expression
in patients seems to decrease quite rapidly (1–2 weeks) following
adoptive transfer unlike what was observed in in vitro conditions,
where it can last several weeks (Burns et al., 2009). This decrease
seems to be associated with lower general transcriptional activity
of the transduced T-cells, in a similar way as for the endogenous
TCR (van Loenen et al., 2011). However, this situation may be
reversed when restimulating transduced cells.
It is also possible to utilize lentiviral platforms (Tsuji et al., 2005;
Yang et al., 2008; Circosta et al., 2009; Jones et al., 2009) as theymay
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provide the beneﬁt of efﬁciently transducing non-dividing cells
with a safer integration proﬁle (Levine et al., 2006) and resistance
to silencing (Frecha et al., 2010). Nonetheless, the use of stimulat-
ing factors such as cytokines is required to achieve desirable levels
of TCR expression (Cavalieri et al., 2003; Jones et al., 2009; Perro
et al., 2010). In mouse settings, a recent comparison of lenti- and
retroviral vectors showed that the latter mediated better results in
TCR-gene transfer assays (Kerkar et al., 2011).
Non-viral means to engineer T-cells would signiﬁcantly reduce
the need for intensive testing of the viral supernatant, reduc-
ing production time. As such, the use of in vitro-transcribed
RNAmolecules introduced by electroporation (Schaft et al., 2006a;
Zhao et al., 2006a) or DNA constructs (Till et al., 2008) represents
an interesting alternative for the gene modiﬁcation of lympho-
cytes, not only for the rapid screening of gene function (Bialer
et al., 2010; Almasbak et al., 2011) but also in potentially thera-
peutic settings (Zhao et al., 2010). On the other hand, the rapid
disappearance of transgene after a few days (Zhao et al., 2006a)
inherent to this transient system represents a major disadvantage
of this approach. Another interesting non-viral approach is based
on the use of the Sleeping Beauty transposon system (Ivics et al.,
1997; Huang et al., 2006). In this system that was “resurrected”
based on fossil sequences found in the genomes of salmonid ﬁsh,
the gene(s) of interest are integrated into the genomeusing a trans-
posase. This system necessitates the concomitant transfer of two
nucleic acid polymers, one being the transposon encoding the
gene(s) of interest and the other the transposase itself. In the con-
text of TCR-gene transfer, the use of this approach has recently
been reported to provide human T-cells with tumor speciﬁcity
(Peng et al., 2009; Jin et al., 2011).
Beyond the type of vector to be used, it is important to note
that as the TCR is a dimer formed of two chains, TCRα and TCRβ,
these have to be expressed simultaneously by the engineered cells.
As the separate introduction of both chains in the recipient chains
has proven difﬁcult and rather ineffective, several vector designs
strategies have been elaborated to facilitate the efﬁcient expression
of the TCR dimer (reviewed in Uckert and Schumacher, 2009).
The two main strategies that have been utilized clinically rely on
the use of either an internal ribosomal entry site (IRES) or a 2A
peptide sequence separating the two chains. One of the potential
drawbacks related to the use of an IRES sequence is the possibility
that the gene downstream of the IRES is expressed at a lesser level
(Ghattas et al., 1991; Mizuguchi et al., 2000). Alternatively, a 2A
peptide sequence, which is employed by several viruses such as the
picornavirus (Szymczak and Vignali, 2005), provide an effective
way to express simultaneously multiple proteins. Indeed, it has
been showed that the 2A peptide can promote a ribosomal “skip.”
We also showed that a furin cleavage site as well as an amino-
acid spacer can be added to the 2A sequence to enhance transgene
expression (Yang et al., 2008). When comparing both approaches
(IRES or 2A peptide) it has been showed that the latter may be
better for efﬁcient TCR expression (Leisegang et al., 2008).
Though most of the TCR-gene transfer studies are based
on αβTCRs targeting an peptide/MHC class I complex, some
reports have also made used of other types of receptors to tar-
get tumor cells both in vitro and in vivo: TCR speciﬁc for minor
antigens (Heemskerk et al., 2003; Mommaas et al., 2005), MHC
II-restricted TCRs (Yang and Baltimore, 2005; Zhao et al., 2006b;
Ha et al., 2010; Kerkar et al., 2011; Straetemans et al., 2012), and
γδTCR (Marcu-Malina et al., 2011).
TCRs is generally thought to be restricted to a single epitope
(not considering altered peptide ligands). Therefore, the possi-
bility that a single TCR would target multiple cancer epitopes
simultaneously would be advantageous. In that regard, an αβTCR
targeting originally an HLA-A0201-restricted MAGE-A3 epitope
was recently isolated and interestingly, it demonstrated reactivity
against multiple MAGE epitopes (Chinnasamy et al., 2011).
Additionally and beyond our present scope, it is also possi-
ble to modify T-cells to express genes other than those encoding
a TCR to redirect T-cell function. These include antibody-based
chimeric-antigen receptor (CAR) and other genes to modulate
the quality of transduced T-cells (reviewed in Kershaw et al.,
2005; Jena et al., 2010; Kohn et al., 2011; Merhavi-Shoham et al.,
2012). Another approach for the direction of T-cell speciﬁcity
was reported lately and is based on bi-speciﬁc molecules termed
immune-mobilizingmonoclonal TCRs against cancer (ImmTACs;
Liddy et al., 2012). These newly developed reagents comprise an
scFv speciﬁc for CD3 (T-cell binding moiety) and a high-afﬁnity
cancer-speciﬁc TCR (tumor targeting moiety) and were shown to
mediate tumor recognition and killing both in vitro and in vivo
(Liddy et al., 2012).
WHICH CELL TO ENGINEER?
One of the basic assumptions when it comes to TCR engineering
for cancer treatment is that since malignant cells ought to present
their tumor antigens via the MHC class I molecules, the appro-
priate effector cells to be genetically modiﬁed ought to be CD8+
T lymphocytes. Nonetheless, due to the complexity of the acquired
immune system and the different T-cell functional subsets, recent
work has been devoted to the importance of the type/subset of
T-cells to be adoptively transferred.
While they represent a minority of the circulating lympho-
cytes, γδ T-cells have the advantage of expressing TCR chains that
apparently do not pair with αβTCR chains (Saito et al., 1988).
Thus, the use of these cells represents an interesting possibil-
ity to prevent the mispairing of the naturally expressed TCR
chains with the exogenous one (van der Veken et al., 2006). Bi-
speciﬁc T-cells represent another possible option (reviewed in
Marr et al., 2012); for example, virus-speciﬁc cells (speciﬁc for
EBV, CMV or Inﬂuenza) can be engineered to express an addi-
tional receptor to target tumor cells (Rossig et al., 2002; Murphy
et al., 2007; Pule et al., 2008; van der Veken et al., 2009). The
use of these cells may considerably reduce off-target effects as
these cells have a deﬁned speciﬁcity and can provide protection
from latent viruses during the immunosuppressed phase prior to
adoptive transfer. In addition, the continuous expression of viral
antigens following initial infection (such as in the case of EBV)
may provide constant stimulation leading to increased persistence
(Pule et al., 2008).
We and others have also attempted at modifying precursor cells
such as hematopoietic stem cells (HSCs; van Lent et al., 2007; Zhao
et al., 2007b), or more recently induced pluripotent stem cells (iPS;
Lei et al., 2011), to express a TCR and to be further differenti-
ated into T-cells using, for example, the OP9-DL1 system. Their
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plasticity, differentiation capability into many T-cell subsets, and
the possible increased potential to persist in the host (correlated
with clinical response; Robbins et al., 2004; Morgan et al., 2006)
represent a formidable advantage over peripheral T-cells and it
was shown that such modiﬁed cells demonstrate anti-tumor func-
tion in vivo (Alajez et al., 2005; Yang and Baltimore, 2005; Ha et al.,
2010). However, one has to bear in mind that a major drawback
lies with their possible transformation induced by retroviral vec-
tors (Hacein-Bey-Abina et al., 2003), though the latter might be
circumvented using lentiviral- or transposon-based platforms.
Another interesting option is the use of certain subsets of dif-
ferentiated T-cells. Following activation, naïve T-cells can turn
into effector cells, effector memory or central memory cells. T-cell
populations derived from the latter were shown to be exquisitely
persistent over time, to further differentiate into both effector and
central memory in vivo, with adequate response to antigenic chal-
lenge, both in a macaque model (Berger et al., 2008) and more
recently for human virus-speciﬁc cells in immunodeﬁcient mice
(Wang et al., 2011). In regard to TCR-transduced cells, these cells
generated ex vivo exhibit mainly a CD62L+/CD45RO+ phenotype
similar to central memory T-cells (Yang et al., 2011). Still, Hinrichs
et al. (2009, 2011) showed that TCR-transduced naïve T lym-
phocytes display increased transgene expression and proliferation
compared to memory cells. Muranski et al. (2011) also found that
Th17-polarized CD4+ T-cells demonstrate enhanced anti-tumor
function, resistance to apoptosis and persistence following adop-
tive transfer with stem-cell likemultipotency signature. The role of
Th17 cells in mediating tumor regression was also recently high-
lighted in a study dealing with the identiﬁcation of tumor antigens
able to mediate tumor regression following immunization (Pulido
et al., 2012). Interestingly, Gattinoni et al. (2011) recently identi-
ﬁed a subset of T-cells (CD45RO−, CCR7+, CD45RA+, CD62L+,
CD27+, CD28+, and IL-7Rα+) that are endowed with both naïve
and memory properties which they termed T memory stem cells
(Tscm). This fascinating subset seems more potent in ACT settings
than naïve, central, or effector memory T lymphocytes. Despite
their rarity, this type of cells can be generated in vitro by stim-
ulating naïve T-cells in the presence of TWS119, a Wnt pathway
activator (Gattinoni et al., 2009, 2011) and based on their poten-
tial, these cells might provide a promising subset to be TCR gene
engineered, which would demonstrate increased reactivity and
persistence over time in patients.
SAFETY ISSUES
Notwithstanding classical gene therapy-related issues that some of
them will be discussed below, manipulating the immune system
and often bypassing tolerance mechanisms can generate immune
toxicities. Previous works have shown that the transfer of tumor
antigen-speciﬁc T-cells can cause autoimmune manifestations
such as ocular toxicity (Palmer et al., 2008) or systemic autoimmu-
nity (Rosenberg et al., 1988) and this subject has been thoroughly
reviewed in Amos et al. (2011).
Still, one the obvious advantages of the use of TCR-engineered
cells in the published clinical trials and pre-clinical studies is
their autologous origin, which certainly eases their engraftment
and long-term persistence. Nevertheless, the expression of trans-
genes mainly from xenogenic provenance (e.g., murine TCRs or
virus-derived 2A peptides) might trigger immunogenicity. Davis
et al. (2010) showed that a little less than a quarter of the patients
administered T-cells expressing fully murine TCRs (speciﬁc for
a human pMHC complex) indeed developed antibodies directed
essentially to the TCR-variable regions. However this response
was not associated with the level of transduced cell persistence or
response to therapy.
A comprehensive study showed that 9 years following gene
modiﬁcation of T-cells with a retrovirally expressed transgene,
these cells demonstrated stable gene expression proﬁles and phe-
notype with no evidence of clonal selection (Recchia et al., 2006).
Additionally, it seems so far that no off-target or GVH disorders
were observed in patients treated at the Surgery branch (NCI)
in seven different TCR-gene transfer clinical protocols (three of
which made use of murine TCR that preferentially pair; Park
et al., 2011). As quoted above, no replication competent viruses
occurrence was observed in hundreds of patients treated with
retrovirally engineered T-cells (Bear et al., 2012).
Nevertheless, one has to bear in mind the possible risks
associated with this kind of gene therapy such as reactivity to nor-
mal tissues expressing the targeted antigen (Johnson et al., 2009;
Parkhurst et al., 2011a), possible newly generated speciﬁcities asso-
ciated with TCR mispairing (Bendle et al., 2010; van Loenen et al.,
2010), and insertional mutagenesis. Several approaches have been
developed to readily eliminate engineered T-cells in case such
adverse events take place. These include in part the inclusion
of suicide genes (Morgan, 2012) such as a inducible Caspase
9 molecular switch (Straathof et al., 2005; de Witte et al., 2008;
Di Stasi et al., 2011) or Herpes Simplex Virus thymidine kinase
(HSV-TK; Bonini et al., 1997) in the vector and subsequent trig-
gering of cellular death using a chemical inducer of dimerization
(CID) or Ganciclovir, respectively. It is also possible to deplete
in vivo TCR-expressing T-cells using antibodies directed against
speciﬁc tags (such as c-myc or HA), provided the cDNA sequences
encoding these peptide tags are added to the 5′-end of the gene(s)
encoding the TCR chains (Kieback et al., 2008). In addition, this
particular TCR-tagging strategy saves the need to include an
additional (suicide) gene in the vector construct.
BEYOND CANCER: TCR-GENE TRANSFER
FOR OTHER DISORDERS
The immune system in general, and T-cells in particular, have
been shown to be critically involved both in host defense and
unfortunately, in immunopathologies (Morris and Allen, 2012).
Thus, the genetic modiﬁcation of T lymphocytes can provide an
attractive way to alter or redirect the immune response in order
to target pathogens or remedy to certain T cell-linked pathologies
(Table 1).
Amongst T-cells, the Treg subset is important for the
immunomodulation of self-reactivity, especially in the case
of autoimmune disorders. It is possible to generate antigen-
speciﬁc Tregs by gene transfer and deﬁned T-cells with regulatory
activity, in order to treat autoimmune disease. Several groups
showed that co-transduction of T-cells with FOXP3 and spe-
ciﬁc TCR created T regulatory cells that were able to suppress
arthritis in different models (Fujio et al., 2006; Wright et al.,
2009), for example, by reduction of Th17 cells and decrease of
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Table 1 | Use ofTCR-gene transfer for non-neoplastic diseases.
Condition Disorder/Pathogen References
Autoimmunity Arthritis Fujio et al. (2006)
Wright et al. (2009)
Systemic autoimmune
disease
Fujio et al. (2004)
Viral infection Cytomegalovirus (CMV) Schub et al. (2009)
Epstein–Barr virus (EBV) Schaft et al. (2006b)
Hart et al. (2008)
Hepatitis B virus (HBV) Gehring et al. (2011)
Hepatitis C virus (HCV) Zhang et al. (2010)
Human immunodeﬁciency
virus (HIV)
Cooper et al. (2000)
Ueno et al. (2004)
Varela-Rohena et al. (2008)
Human papilloma virus
(HPV)
Scholten et al. (2005, 2011)
Inﬂuenza virus Kessels et al. (2001)
Microbial Mycobacterium Luo et al. (2011)
infection tuberculosis
bone destruction (Wright et al., 2009). Still in this study, TCR-
redirected natural Tregs showed a better therapeutic potential
than FOXP3-transduced cells. In addition, redirected regula-
tory T-cells speciﬁc for nucleosome antigen were shown to
suppress a systemic autoimmune disease in a mouse model
(Fujio et al., 2004).
TCR-gene transfer approaches could also be implemented for
the redirection of T-cell response against HIV. For example,
Cooper et al. (2000) showed more than a decade ago that T-
cells can be transduced with a GAG-speciﬁc TCR and target cells
displaying the relevant epitope. Other HIV antigens were also
targeted similarly by TCR-transduced T-cells speciﬁc for POL.
The engineered lymphocytes showed potent inhibitory activity
against HIV-1 replication in vitro and substantial cytotoxic activ-
ity and cytokine production triggered by either epitope-pulsed or
infected with HIV-1 target cells (the functional phenotype was
similar to those of the parental CTL clone) (Ueno et al., 2004).
Using an afﬁnity-enhanced codon-optimized GAG-speciﬁc TCR,
Varela-Rohena et al. (2008) were able to demonstrate very high
level of TCR expression that translated into a high sensitivity to
the presence of low levels of cognate epitopes on APCs, including
escape mutants.
Additionally, recent studies have focused on the possibility of
engineering T-cells to recognize other viral epitopes. For example,
a CD8-independent HCV-speciﬁc TCR was isolated and con-
ferred reactivity to both CD4 and CD8 T-cells, leading to the
recognition of HCV+ hepatoma cells (Zhang et al., 2010). Other
reports have exempliﬁed the potential of TCR-gene transfer strat-
egy to target CMV (Schub et al., 2009), EBV (Schaft et al., 2006b;
Hart et al., 2008), HBV (Gehring et al., 2011), and HPV (Scholten
et al., 2005, 2011).
Lately, this approach has been extended to bacterial anti-
gens. As adoptive transfer of Mycobacterium tuberculosis-speciﬁc
effector T-cells has been shown to confer immunity to infected
recipients (Woodworth et al., 2008; Duffy et al., 2009), Luo et al.
(2011) aimed at adapting TCR-gene transfer approach to gener-
ate anti-bacterial immunity. They isolated M. tuberculosis 38-kDa
antigen speciﬁcHLA class I and class II-restricted TCRs and subse-
quently minimally murinized their constant regions (Bialer et al.,
2010; Sommermeyer and Uckert, 2010) to enhance their expres-
sion and function. When introduced in CD8+ and CD4+ T-cells,
respectively, these TCRs where shown to trigger speciﬁc cytokine
secretion by T-cells in co-culture with antigen-pulsed DCs, as
well as cell-mediated cytotoxicity (by the CD8+ population)
(Luo et al., 2011).
CONCLUSIONS AND FUTURE DIRECTIONS
TCR-gene modiﬁcations of primary human T-cells have demon-
strated over the past decade signiﬁcant achievements, the most
important one being its encouraging translation from bench to
bedside. In the past few years, successful gene-therapy studies
have renewed hopes with regard to the ability to genetically mod-
ify patient cells for therapeutic purposes (Kay, 2011; Sheridan,
2011). Unlike for monogenic diseases, the broader implemen-
tation of TCR-gene transfer as a semi-personalized medicine
approach would require the isolation and the characterization of
multiple TCRs, due to HLA polymorphism and the variety of
tumor antigens that would need to be targeted. The nature of the
antigen, its exquisite expression by the tumor, but more impor-
tantly, its immunogenicity and its capacity to evoke efﬁcient
tumor response will be a crucial determinant for the success of
this kind of therapy. More needs to be understood about anti-
gen immunodominance and the kinetics and dynamics of tumor
antigen expression, even if impressive tumor regressions were
observed in patients treated with monospeciﬁc engineered T-
cells (Morgan et al., 2006; Johnson et al., 2009; Park et al., 2011;
Robbins et al., 2011). In this regard, extensive screening of tumor
reactive T-cells such as TILs may provide valuable information
about the speciﬁcity of the anti-tumor T-cell response in can-
cer patients (Andersen et al., 2012). Additionally, the functional
characterization of the ability of antigens tomediate tumor regres-
sion will provide critical insight as to which epitope(s) TCRs
should be speciﬁc for (Pulido et al., 2012). Needless to say that
the widespread implementation of such “off-the shelf” gene-
therapy protocols will beneﬁt from the development of approaches
for in vivo infection as well as from a better understanding of
the cell selection and conditioning process. The combination of
newly immunomodulating agents and/or vaccination strategymay
improve the clinical response rates (Mellman et al., 2011). Over-
all, the ability of redirecting the speciﬁcity of T-cells genetically
holds great promise for the immunotherapy of cancer and other
diseases.
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